Cargando…
Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations in JAK2 can result in the constitutive activation of STAT transcription factors and lead to oncogenic growth. JAK kinases are established Hsp90 client proteins and here w...
Autores principales: | Proia, David A., Foley, Kevin P., Korbut, Tim, Sang, Jim, Smith, Don, Bates, Richard C., Liu, Yuan, Rosenberg, Alex F., Zhou, Dan, Koya, Keizo, Barsoum, James, Blackman, Ronald K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077378/ https://www.ncbi.nlm.nih.gov/pubmed/21533169 http://dx.doi.org/10.1371/journal.pone.0018552 |
Ejemplares similares
-
HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma
por: Guan, Liuliu, et al.
Publicado: (2020) -
Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011) -
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
por: Goldman, Jonathan W, et al.
Publicado: (2013) -
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012) -
Hsp90 Inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma
por: Tan, Wenchong, et al.
Publicado: (2022)